Roche may have scuttled its prostate cancer collaboration with Inovio, but it hasn’t shaken the latter company’s confidence in its pipeline.
Instead, the Pennsylvania drugmaker said in a statement Monday that it would continue to develop its experimental immuno-oncology drug INO-5150, and said it expects to kick off Phase-I clinical trials in the first half of next year. The treatment targets both the prostate-specific membrane antigen as well as the prostate-specific antigen.
Inovio and Roche remain linked in the hepatitis B space, and will continue to develop INO-1800.
